title: Drug Susceptibility Assessment in Stenotrophomonas Maltophilia Strains Isolated From the Blood of Organ Transplantation Recipients in a Warsaw Teaching Hospital During 2011 to 2014.
abstract: BACKGROUND
  Blood infections with multidrug-resistant Gram-negative carbapenem-resistant bacilli are particularly dangerous and challenging to treat in organ transplant recipients. Resistance to carbapenems may be acquired, for example, in Enterobacteriaceae, Pseudomonas, or Acinetobacter spp. or innate, for example, in Stenotrophomonas maltophilia. The purpose of this study was to analyze blood infections caused by S maltophilia in organ transplant recipients and to compare drug susceptibility of these bacteria and the same species isolated from the blood of other inpatients.
  
  
  METHODS
  A total of 26 S maltophilia strains isolated from blood samples of 26 patients (including 14 liver or kidney transplant recipients) hospitalized during 2011 to 2014 were evaluated in this study. Antibiotic susceptibility was determined via E-test and disk diffusion methods.
  
  
  RESULTS
  Stenotrophomonas maltophilia strains isolated from blood exhibited sensitivity to trimethoprim/sulfamethoxazole (100%), levofloxacin (96.2%), ciprofloxacin (92.3%), ticarcillin/clavulanic acid (80.8%), and ceftazidime (53.9%).
  
  
  CONCLUSIONS
  Because appropriate antibiotic therapy in the case of S maltophilia differs from the standard empirical therapy administered in the case of most other Gram-negative bacilli, early identification of this pathogen is of particular significance. The use of antibiotics to which this pathogen is sensitive eliminates the infection and helps avoid graft loss.
authors: Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland; Department of Medical Microbiology, The Infant Jesus Teaching Hospital, Warsaw, Poland.
authors: P
authors: P
authors: Usarek
authors: Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland; Department of Medical Microbiology, The Infant Jesus Teaching Hospital, Warsaw, Poland.
authors: K
authors: K
authors: Dobrzaniecka
authors: Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland; Department of Medical Microbiology, The Infant Jesus Teaching Hospital, Warsaw, Poland. Electronic address: xenia.szymanek@wum.edu.pl.
authors: K
authors: K
authors: Szymanek-Majchrzak
authors: Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland; Department of Medical Microbiology, The Infant Jesus Teaching Hospital, Warsaw, Poland.
authors: A
authors: A
authors: Sawicka-Grzelak
authors: Department of Medical Microbiology, The Infant Jesus Teaching Hospital, Warsaw, Poland; Department of Dental Microbiology, Medical University of Warsaw, Warsaw, Poland.
authors: A
authors: A
authors: Mlynarczyk
authors: Department of Transplant Medicine and Nephrology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
authors: M
authors: M
authors: Durlik
authors: Department of Immunology, Transplantology and Internal Diseases, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
authors: M
authors: M
authors: Ciszek
authors: Department of Immunology, Transplantology and Internal Diseases, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
authors: L
authors: L
authors: Paczek
authors: Department of General and Transplantation Surgery, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
authors: A
authors: A
authors: Chmura
authors: Department of General and Transplantation Surgery, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
authors: A
authors: A
authors: Kwiatkowski
authors: Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland; Department of Medical Microbiology, The Infant Jesus Teaching Hospital, Warsaw, Poland.
authors: G
authors: G
authors: Mlynarczyk
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002442:Ceftazidime / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D002969:Clavulanic Acids / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D006784:Hospitals, Teaching; D006801:Humans; D064704:Levofloxacin / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D016377:Organ Transplantation / Q000009:adverse effects*; D020615:Stenotrophomonas maltophilia; D013982:Ticarcillin / Q000627:therapeutic use; D066027:Transplant Recipients / Q000706:statistics & numerical data; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D002939:Ciprofloxacin; D064704:Levofloxacin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; C043215:ticarcillin-clavulanic acid; D002442:Ceftazidime; D013982:Ticarcillin